

# The CDC recommends Beyfortus<sup>®</sup> for infants aged <8 months between October 1 and March 31<sup>1\*</sup>

Every infant should have a routine well-baby visit during their first RSV season where they can receive Beyfortus<sup>1,2</sup>

RSV is seasonal, with infections peaking at certain times throughout the year. A typical RSV season runs roughly from fall through spring, with some exceptions, such as in Florida and Hawaii, where the RSV season may start earlier. In most of the continental US, RSV typically peaks between December and January. Per CDC, administration of Beyfortus is recommended from October 1 through March 31.<sup>1,3-6</sup>

**CDC recommends to administer Beyfortus starting in October to infants born before the typical RSV season<sup>1,2,6\*</sup>**

Birth month						CDC-recommended administration period*					
Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar
						6 mo					
							6 mo				
						4 mo		6 mo			
							4 mo		6 mo		
						2 mo		4 mo		6 mo	
						1 mo	2 mo		4 mo		6 mo

 Infant birth       Optimal administration window      Month markers represent regularly scheduled well-baby visits.

\*Timing of administration for RSV immunization may differ in certain areas.<sup>1</sup>

**For infants born during the RSV season, administer Beyfortus at the earliest opportunity.<sup>1</sup>**

CDC, Centers for Disease Control and Prevention; RSV, respiratory syncytial virus.

## INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

## IMPORTANT SAFETY INFORMATION

### Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

**Please see additional Important Safety Information on the following page and accompanying full Prescribing Information.**

 **Beyfortus<sup>®</sup>** (nirsevimab-alip) | 50 mg  
100 mg  
Injection

# How you can help protect infants against RSV disease



## Before the RSV season

- During office visits, educate parents on RSV seasonality and RSV disease
- Provide Beyfortus® and RSV educational materials to parents



## Right before the RSV season

- Ensure Beyfortus is stocked
- Retrain staff on the dosing and administration of Beyfortus
- Use your Electronic Health Record (EHR) system to identify eligible patients
- Inform parents Beyfortus is available and their infant can receive it at their next well-baby visit
- Provide Beyfortus and RSV educational materials to parents
- Start to administer Beyfortus to infants born before RSV season during their well-baby visits



## During the RSV season

- Continue to administer Beyfortus to infants during their well-baby visits
- Within the EHR system, identify patients who are 7 months old and haven't received protection against RSV disease
  - Schedule patients for a well-baby visit for Beyfortus administration before they age out of ACIP recommendations
- Screen patients at sick visits to administer Beyfortus
- Provide Beyfortus and RSV educational materials to parents

## IMPORTANT SAFETY INFORMATION (cont'd)

### Warnings and Precautions

- **Hypersensitivity Reactions Including Anaphylaxis:** Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

**Please see additional Important Safety Information on the previous page and accompanying full Prescribing Information.**



Sanofi can provide resources and support at every step.  
Contact your Sanofi representative to learn more.

ACIP, Advisory Committee on Immunization Practices.

**References:** **1.** Immunizations to protect infants. Centers for Disease Control and Prevention. Updated August 30, 2024. Accessed April 29, 2025. <https://www.cdc.gov/rsv/vaccines/protect-infants.html> **2.** Recommendations for preventive pediatric health care. Bright Futures/American Academy of Pediatrics. Updated February 2025. Accessed April 29, 2025. [https://downloads.aap.org/AAP/PDF/periodicity\\_schedule.pdf](https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf) **3.** Surveillance of RSV. Centers for Disease Control and Prevention. Updated August 30, 2024. Accessed April 29, 2025. <https://www.cdc.gov/rsv/php/surveillance/index.html> **4.** Rose EB, Wheatley A, Langley G, et al. Respiratory syncytial virus seasonality-United States, 2014-2017. *MMWR Morb Mortal Wkly Rep.* 2018;67(2):71-76. **5.** Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi. **6.** RSV immunization guidance for infants and young children. Centers for Disease Control and Protection. Updated August 30, 2024. Accessed May 5, 2025. <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html>

**sanofi**

SANOFI  
1 Discovery Drive, Swiftwater, PA 18370  
© 2025 Sanofi. All rights reserved.  
MAT-US-2505010-v1.0-05/2025

**Beyfortus**<sup>®</sup> | 50 mg  
(nirsevimab-alip) | 100 mg  
Injection